Table 3.
Summary of inorganic substance-based PECs inhibitors.
| Inhibitor | Testing model | CC50 (μmol/L or others) | Main phases of action | Viruses | Ref. |
|---|---|---|---|---|---|
| Lithium chloride (LiCl) | In vitro | > 5.0 × 104 | Entry, replication | TGEV | (Ren et al. 2011) |
| In vitro | > 1.5 × 104 | Entry, replication | PEDV | (Li et al. 2018) | |
| In vitro | > 6 × 104 | Entry, replication | PDCoV | (Zhai et al. 2019) | |
| Graphene oxide | In vitro | > 50 μg/mL | Entry, replication | PEDV | (Ye et al. 2015) |
| Te/BSA NPs | In vitro | > 30 μg/mL | Entry | PEDV | (Zhou et al. 2020a) |
| Ag2S nanoclusters | In vitro | > 184 μg/mL | Replication | PEDV | (Du et al. 2018a) |
| Silver nanoparticle-modified graphene oxide nanocomposites | In vitro | > 8.0 μg/mL | Entry, replication | PEDV | (Du et al. 2018b) |
| Au@Ag nanorods | In vitro | > 0.16 | Entry, replication | PEDV | (Du et al. 2020) |
| Zinc sulfide nanoparticles | In vitro | > 1.20 mg/mL | Entry, replication | PEDV | (Zhou et al. 2020b) |
| Gly-CDs | In vitro | > 0.90 mg/mL | Entry, replication | PEDV | (Tong et al. 2020) |
| Selenium Nano-Particles | In vitro | > 10 μg/mL | Replication | PDCoV | (Ren et al. 2022d) |
| Zinc chloride | In vitro | 321 | Replication, release | TGEV | (Wei et al. 2012) |
| Zinc sulfate | In vitro | 343 | Replication, release | TGEV | (Wei et al. 2012) |
| Ag nanoparticles (Ag NPs) | In vitro | > 12.5 μg/mL | Entry, replication | TGEV | (Lv et al. 2014) |
| NM-300 | In vitro | > 12.5 μg/mL | Entry, replication | TGEV | (Lv et al. 2014) |
| Silver nanowires (XFJ011) | In vitro | > 12.5 μg/mL | Entry, replication | TGEV | (Lv et al. 2014) |
| Silver colloids (XFJ04) | In vitro | > 12.5 μg/mL | Entry, replication | TGEV | (Lv et al. 2014) |